Category: PAD

“Impressive” 12-month Flex vessel prep data presented at VEITHsymposium

VentureMed Group, a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced data presented at the VEITHsymposium, (15–19 November, New York, USA). Overall, the data presented demonstrated that Flex vessel prep used prior to balloon angioplasty improves 12-month […]

The post “Impressive” 12-month Flex vessel prep data presented at VEITHsymposium appeared first on Vascular News.

VSGBI President’s Symposium spotlights data-driven financial incentives for PAD revascularisation

The President’s Symposium at the Vascular Society of Great Britain and Ireland (VSGBI) annual scientific meeting (23–25 November, Brighton, UK) featured Rob Sayers’ (University of Leicester, UK) presentation titled ‘CLTI CQUIN has raised the profile of PAD and will lead to fewer amputations’. Sayers’ take-home message for delegates was that the National Health Service (NHS)’s […]

The post VSGBI President’s Symposium spotlights data-driven financial incentives for PAD revascularisation appeared first on Vascular News.

Chocolate Touch drug-coated angioplasty balloon for treatment of PAD receives FDA approval

Genesis MedTech Group announced that the US Food and Drug Administration (FDA) has approved the Chocolate Touch drug-coated balloon (DCB) percutaneous transluminal angioplasty (PTA) catheter, developed by TriReme Medical, for the treatment of patients with peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and the popliteal artery.  The Chocolate Touch DCB was shown […]

The post Chocolate Touch drug-coated angioplasty balloon for treatment of PAD receives FDA approval appeared first on Vascular News.

Vascular News’ top 10 most popular stories of September 2022

September’s top 10 highlights a randomised trial that aims to examine early endovascular aneurysm repair (EVAR) in women, new radiation safety guidelines from the European Society for Vascular Surgery (ESVS), and the latest data from renal denervation trials, among various other updates from the vascular surgery world. 1. WARRIORS randomised trial aims to examine early […]

The post Vascular News’ top 10 most popular stories of September 2022 appeared first on Vascular News.

First patient enrolled in BIONETIC-I study of iliac artery treatment with Biotroniks’s Dynetic-35 stent system

Biotronik has announced the first patient enrolment in the BIONETIC-I study of the safety and efficacy of the Dynetic-35 cobalt chromium balloon-expandable stent system for the treatment of atherosclerotic peripheral arterial disease (PAD) lesions in the iliac arteries. The study will also evaluate the use of the stent system in association with Biotroniks’s Passeo-35 Xeo […]

The post First patient enrolled in BIONETIC-I study of iliac artery treatment with Biotroniks’s Dynetic-35 stent system appeared first on Vascular News.

Japanese Selution SLR study completes enrolment

MedAlliance, with its Japanese partner MDK Medical, has completed enrolment in the clinical study of its novel sirolimus drug-eluting balloon (DEB), Selution SLR, for the treatment of peripheral arterial disease (PAD). This follows the acceptance of a Clinical Trial Notification (CTN) by Japan’s Pharmaceutical and Medical Device Agency (PMDA) in June 2020.  The study involves […]

The post Japanese Selution SLR study completes enrolment appeared first on Vascular News.

Femoropopliteal bypass shows reintervention benefit over endovascular therapy for advanced premature PAD

Femoropopliteal bypass is associated with decreased reinterventions at one year compared to endovascular therapy in patients with advanced premature peripheral arterial disease (PAD). This is the primary conclusion of Tanner I Kim (Yale School of Medicine, New Haven, USA) and colleagues, writing in an article recently published online in the Journal of Vascular Surgery. The […]

The post Femoropopliteal bypass shows reintervention benefit over endovascular therapy for advanced premature PAD appeared first on Vascular News.

ACC 2021: VOYAGER-PAD analysis shows totality of ischaemic events reduced following rivaroxaban use

Rupert Bauersachs (Darmstadt, Germany) talks to Cardiovascular News about the VOYAGER-PAD trial, the results of which he presented at the American College of Cardiology’s 70th Annual Scientific Session (ACC.21, 15–17 May, virtual) and which highlighted a reduced risk of ischaemic events in peripheral artierial disease (PAD) patients receiving rivaroxaban. The analysis, presented by Bauersachs, focused […]

The post ACC 2021: VOYAGER-PAD analysis shows totality of ischaemic events reduced following rivaroxaban use appeared first on Vascular News.